The content on this site is intended for healthcare professionals only
Dr Elias Jabbour speaks to ecancer about the phase 3 Phallcon Study. This study compared ponatinib to imatinib in patients with newly diagnosed Ph+ ALL.
The study found that ponatinib was superior to imatinib in combination with reduced-intensity chemotherapy in the front-line setting for patients with Ph+ ALL, with a clinically significantly higher MRD-neg complete response rate at the end of induction.
The benefit of this regimen was noticed across all subgroups, particularly for patients ≥60 years and for those with the BCR::ABL1 p190 variant.
Treating relapsed multiple myeloma outside of use of T-cell redirected therapies
Isatuximab, plus bortezomib, lenalidomide, and dexamethasone shows improved PFS in frail NDMM patients
Isa-KRd quad regimen in NDMM: MIDAS and CONCEPT studies
EHA 2024: Multiple myeloma roundup
More effective treatment options required for patients with MM post lenalidomide exposure
Isatuximab in combination with pomalidomide and dexamethasone shows promising efficacy in 2nd line RRMM
ASCO 2024: Two studies report on isatuximab combos in transplant-ineligible patients with newly diagnosed multiple myeloma
Multiple myeloma in a resource constrained setting
Ide-cell enhances health-related quality of life for refractory multiple myeloma
